Tags

Type your tag names separated by a space and hit enter

Cancers in Australia in 2010 attributable to and prevented by the use of combined oral contraceptives.
Aust N Z J Public Health. 2015 Oct; 39(5):441-5.AN

Abstract

OBJECTIVES

To estimate the proportion and number of cancers occurring in Australia in 2010 attributable to combined oral contraceptive pill (OCP) use.

METHODS

We estimated the population attributable fraction (PAF) for cancers causally associated with combined OCP use (breast, cervix), and the proportion of endometrial and ovarian cancers prevented (prevented fraction [PF]). We used standard formulae incorporating prevalence of combined OCP use in the Australian population, relative risks of cancer associated with this exposure and cancer incidence.

RESULTS

An estimated 105 breast and 52 cervical cancers (0.7% and 6.4% of each cancer, respectively) in Australia in 2010 were attributable to current use of combined OCP. Past combined OCP use was estimated to have prevented 1,032 endometrial and 308 ovarian cancers in 2010, reducing the number of cancers that would otherwise have occurred by 31% and 19%, respectively.

CONCLUSIONS

A small proportion of breast and cervical cancers is attributable to combined OCP use; OCP use is likely to have prevented larger numbers of endometrial and ovarian cancers.

IMPLICATIONS

Women seeking contraceptive advice should be told of potential adverse effects, but should also be told that - along with reproductive health benefits - combined OCP use can reduce long-term risks of ovarian and endometrial cancers.

Authors+Show Affiliations

QIMR Berghofer Medical Research Institute, Queensland. School of Public Health, The University of Queensland.QIMR Berghofer Medical Research Institute, Queensland.QIMR Berghofer Medical Research Institute, Queensland. School of Public Health, The University of Queensland.QIMR Berghofer Medical Research Institute, Queensland. School of Public Health, The University of Queensland. Cancer Research UK, Manchester Institute and Institute of Inflammation and Repair, University of Manchester, United Kingdom.QIMR Berghofer Medical Research Institute, Queensland. School of Public Health, The University of Queensland.QIMR Berghofer Medical Research Institute, Queensland. National Centre for Epidemiology and Population Health, Research School of Population Health, Australian National University, Australian Capital Territory.QIMR Berghofer Medical Research Institute, Queensland. School of Public Health, The University of Queensland.QIMR Berghofer Medical Research Institute, Queensland. School of Public Health, The University of Queensland.QIMR Berghofer Medical Research Institute, Queensland. School of Public Health, The University of Queensland.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26437729

Citation

Jordan, Susan J., et al. "Cancers in Australia in 2010 Attributable to and Prevented By the Use of Combined Oral Contraceptives." Australian and New Zealand Journal of Public Health, vol. 39, no. 5, 2015, pp. 441-5.
Jordan SJ, Wilson LF, Nagle CM, et al. Cancers in Australia in 2010 attributable to and prevented by the use of combined oral contraceptives. Aust N Z J Public Health. 2015;39(5):441-5.
Jordan, S. J., Wilson, L. F., Nagle, C. M., Green, A. C., Olsen, C. M., Bain, C. J., Pandeya, N., Whiteman, D. C., & Webb, P. M. (2015). Cancers in Australia in 2010 attributable to and prevented by the use of combined oral contraceptives. Australian and New Zealand Journal of Public Health, 39(5), 441-5. https://doi.org/10.1111/1753-6405.12444
Jordan SJ, et al. Cancers in Australia in 2010 Attributable to and Prevented By the Use of Combined Oral Contraceptives. Aust N Z J Public Health. 2015;39(5):441-5. PubMed PMID: 26437729.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cancers in Australia in 2010 attributable to and prevented by the use of combined oral contraceptives. AU - Jordan,Susan J, AU - Wilson,Louise F, AU - Nagle,Christina M, AU - Green,Adele C, AU - Olsen,Catherine M, AU - Bain,Christopher J, AU - Pandeya,Nirmala, AU - Whiteman,David C, AU - Webb,Penelope M, PY - 2015/03/01/received PY - 2015/04/01/revised PY - 2015/05/01/accepted PY - 2015/10/7/entrez PY - 2015/10/7/pubmed PY - 2016/7/12/medline KW - cancer KW - infection KW - population attributable fraction KW - risk factor SP - 441 EP - 5 JF - Australian and New Zealand journal of public health JO - Aust N Z J Public Health VL - 39 IS - 5 N2 - OBJECTIVES: To estimate the proportion and number of cancers occurring in Australia in 2010 attributable to combined oral contraceptive pill (OCP) use. METHODS: We estimated the population attributable fraction (PAF) for cancers causally associated with combined OCP use (breast, cervix), and the proportion of endometrial and ovarian cancers prevented (prevented fraction [PF]). We used standard formulae incorporating prevalence of combined OCP use in the Australian population, relative risks of cancer associated with this exposure and cancer incidence. RESULTS: An estimated 105 breast and 52 cervical cancers (0.7% and 6.4% of each cancer, respectively) in Australia in 2010 were attributable to current use of combined OCP. Past combined OCP use was estimated to have prevented 1,032 endometrial and 308 ovarian cancers in 2010, reducing the number of cancers that would otherwise have occurred by 31% and 19%, respectively. CONCLUSIONS: A small proportion of breast and cervical cancers is attributable to combined OCP use; OCP use is likely to have prevented larger numbers of endometrial and ovarian cancers. IMPLICATIONS: Women seeking contraceptive advice should be told of potential adverse effects, but should also be told that - along with reproductive health benefits - combined OCP use can reduce long-term risks of ovarian and endometrial cancers. SN - 1753-6405 UR - https://www.unboundmedicine.com/medline/citation/26437729/Cancers_in_Australia_in_2010_attributable_to_and_prevented_by_the_use_of_combined_oral_contraceptives_ L2 - https://doi.org/10.1111/1753-6405.12444 DB - PRIME DP - Unbound Medicine ER -